BioSpace News Archive

Todos Medical, Ltd. today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory, Provista Diagnostics, Inc., is expanding its onsite school sample collection programs for COVID-19 PCR testing to include MonkeyPox testing.

Prolacta Bioscience ®, the world’s leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, celebrated Breastfeeding Awareness Month by recognizing the commitment of NICU parents to their infants’ health through advocating for and/or providing essential human milk nutrition.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International Tennis Hall of Fame member Chris Evert as a special guest at its inaugural Illumina Genomics Forum (IGF) on October 1.

GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022.

This month, Inc. revealed that Neurolens has been recognized on its annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America.

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced the acquisition of Midway Dental Supply, a full-service dental distributor serving dental offices and dental laboratories across the Midwestern United States.

The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop and commercialize drug products applying ZERION’s solubility enhancing Dispersome® technology.

The sepsis diagnostic market is likely to expand at a noteworthy pace in the forthcoming year because of the increasing burden of sepsis around the world.

VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, announced its launch today.

The global asthma treatment market will rise from a value of ~US$ 25.6 Bn in 2019 to ~US$ 30.5 Bn by 2027, and it is anticipated that an increase in the number of FDA-approved products in parallel to the increasing awareness among asthma patients regarding quality care will drive the steady odyssey of the market.